Discover the inspiring weight loss journey of a dietitian who overcame PCOS and pregnancy challenges to achieve lasting ...

MASH is a culmination of steatosis, inflammation, and fibrosis, and is also associated with comorbidities such as obesity and ...

A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...

Weight loss tops many folks' list of New Year's resolutions, and lots of people are turning to cutting-edge weight-loss drugs ...

This may start to bring down the cost of brand-name competitors—here's who might get access, and one major difference from ...

Figuring out if GLP-1s are the right fit for you isn’t something to tackle alone—and that’s where Mochi Health comes in.

Generic Victoza is a GLP-1 receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes ...

According to Ian Neeland, MD, strategies like pharmacist-led counseling, patient education programs, and patient assistance ...